231 related articles for article (PubMed ID: 23979954)
1. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.
Goldberg R; Temprosa M; Otvos J; Brunzell J; Marcovina S; Mather K; Arakaki R; Watson K; Horton E; Barrett-Connor E
J Clin Endocrinol Metab; 2013 Oct; 98(10):3989-98. PubMed ID: 23979954
[TBL] [Abstract][Full Text] [Related]
2. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
[TBL] [Abstract][Full Text] [Related]
3. The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program.
Golden SH; Kim C; Barrett-Connor E; Nan B; Kong S; Goldberg R;
Metabolism; 2013 Sep; 62(9):1313-22. PubMed ID: 23660512
[TBL] [Abstract][Full Text] [Related]
4. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
[TBL] [Abstract][Full Text] [Related]
5. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
[TBL] [Abstract][Full Text] [Related]
6. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Aroda VR; Christophi CA; Edelstein SL; Zhang P; Herman WH; Barrett-Connor E; Delahanty LM; Montez MG; Ackermann RT; Zhuo X; Knowler WC; Ratner RE;
J Clin Endocrinol Metab; 2015 Apr; 100(4):1646-53. PubMed ID: 25706240
[TBL] [Abstract][Full Text] [Related]
7. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.
Perreault L; Kahn SE; Christophi CA; Knowler WC; Hamman RF;
Diabetes Care; 2009 Sep; 32(9):1583-8. PubMed ID: 19587364
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
[TBL] [Abstract][Full Text] [Related]
9. Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions.
Goldberg RB; Bray GA; Marcovina SM; Mather KJ; Orchard TJ; Perreault L; Temprosa M;
Diabetologia; 2019 Jan; 62(1):58-69. PubMed ID: 30334082
[TBL] [Abstract][Full Text] [Related]
10. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.
Florez H; Pan Q; Ackermann RT; Marrero DG; Barrett-Connor E; Delahanty L; Kriska A; Saudek CD; Goldberg RB; Rubin RR;
J Gen Intern Med; 2012 Dec; 27(12):1594-601. PubMed ID: 22692637
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of lifestyle and metformin interventions in DPP on bone density.
Schwartz AV; Pan Q; Aroda VR; Crandall JP; Kriska A; Piromalli C; Wallia A; Temprosa M; Florez H;
Osteoporos Int; 2021 Nov; 32(11):2279-2287. PubMed ID: 34086101
[TBL] [Abstract][Full Text] [Related]
12. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.
Goldberg RB; Temprosa MG; Mather KJ; Orchard TJ; Kitabchi AE; Watson KE;
Diabetes Care; 2014 Aug; 37(8):2253-60. PubMed ID: 24824548
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention.
Fu JF; Liang L; Zou CC; Hong F; Wang CL; Wang XM; Zhao ZY
Int J Obes (Lond); 2007 Jan; 31(1):15-22. PubMed ID: 16953257
[TBL] [Abstract][Full Text] [Related]
15. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
[TBL] [Abstract][Full Text] [Related]
16. Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.
Eppinga RN; Hartman MH; van Veldhuisen DJ; Lexis CP; Connelly MA; Lipsic E; van der Horst IC; van der Harst P; Dullaart RP
PLoS One; 2016; 11(1):e0145719. PubMed ID: 26808474
[TBL] [Abstract][Full Text] [Related]
17. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
18. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.
Pollin TI; Isakova T; Jablonski KA; de Bakker PI; Taylor A; McAteer J; Pan Q; Horton ES; Delahanty LM; Altshuler D; Shuldiner AR; Goldberg RB; Florez JC; Franks PW;
PLoS Genet; 2012; 8(8):e1002895. PubMed ID: 22951888
[TBL] [Abstract][Full Text] [Related]
19. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.
; Crandall J; Schade D; Ma Y; Fujimoto WY; Barrett-Connor E; Fowler S; Dagogo-Jack S; Andres R
J Gerontol A Biol Sci Med Sci; 2006 Oct; 61(10):1075-81. PubMed ID: 17077202
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
